Biogen and Swedish Orphan Biovitrum have started two paediatric trials of the companies’ long-lasting recombinant Factor VIII and Factor IX Fc fusion proteins (rFVIIIFc and rFIXFc) in haemophilia A and B.

The open-label, multicentre studies are designed to evaluate the safety, pharmacokinetics and efficacy of rFVIIIFc and rFIXFc in previously treated children under the age of 12 years with severe haemophilia A or B.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Glenn Pierce, Biogen’s haemophilia therapeutic area chief medical officer and global medical affairs senior vice president, said: "The paediatric clinical trials are an important complement to the ongoing adult studies and further demonstrate our commitment to develop new treatments for the haemophilia community."

The first patients have already been dosed in the rFIXFc paediatric study, and the rFVIIIFc paediatric study is now actively recruiting patients.

"The paediatric clinical trials are an important complement to the ongoing adult studies."

The Kids A-LONG study will evaluate rFVIIIFc in the prevention and treatment of bleeding episodes in previously treated paediatric patients with haemophilia A.

The frequency of inhibitor development over an approximately 26-week treatment period and at least 50 exposure days to rFVIIIFc are the primary outcome measures. The number of annualised bleeding episodes and assessments of response to treatment over the same time period are the secondary outcome measures of the paediatric study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Similarly, rFIXFc will be evaluated in the Kids B-LONG study for the prevention and treatment of bleeding episodes in previously-treated paediatric patients with haemophilia B.

The primary outcome measure is the frequency of inhibitor development over an approximately 50-week treatment period and at least 50 exposure days to rFIXFc.

Secondary outcome measures include the number of annualised bleeding episodes and assessments of response to treatment over the same time period.

Clinical development head at Swedish Orphan Biovitrum, An van Es-Johansson, said: "With these studies, we extend the clinical development of rFVIIIFc and rFIXFc to address a broader patient population including children with haemophilia."